A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Ovarian Neoplasms · Breast Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 37 (planned)
- Started
- Apr 16, 2021
- Main results expected
- Dec 28, 2026
- Fully finished
- Dec 28, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI)
Measured over: Up to 5 years
Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance status
Measured over: Up to 5 years
Number of participants with clinically significant changes in hematology and clinical chemistry parameters
Measured over: Up to 5 years
Number of participants with clinically significant changes in vital signs
Measured over: Up to 5 years
Number of participants with clinically significant changes in physical examination
Measured over: Up to 5 years
Number of participants with use of concomitant medications
Measured over: Up to 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04641247 · record last updated 2026-06-24 · checked 2026-11-09 15:47 UTC